Your browser doesn't support javascript.
loading
Epigenetic Targeting of Heparan Sulfate 3-O- and 6-O-Sulfation in Breast Cancer Cells: Prospects for Attenuating Prothrombotic Tumor Cell Activities.
Bückreiß, Nico; Schulz-Fincke, Marie; König, Philipp; Maccarana, Marco; van Kuppevelt, Toin H; Li, Jin-Ping; Götte, Martin; Bendas, Gerd.
Affiliation
  • Bückreiß N; Pharmaceutical Institute, Pharmaceutical and Cell Biological Chemistry, University of Bonn, 53121 Bonn, Germany.
  • Schulz-Fincke M; Pharmaceutical Institute, Pharmaceutical and Cell Biological Chemistry, University of Bonn, 53121 Bonn, Germany.
  • König P; Pharmaceutical Institute, Pharmaceutical and Cell Biological Chemistry, University of Bonn, 53121 Bonn, Germany.
  • Maccarana M; Department of Medical Biochemistry and Microbiology, SciLifeLab Uppsala, The Biomedical Center, University of Uppsala, 75123 Uppsala, Sweden.
  • van Kuppevelt TH; Department of Biochemistry, Nijmegen Center for Molecular Life Sciences, Radboud University Nijmegen Medical Center, 6500 HB Nijmegen, The Netherlands.
  • Li JP; Department of Medical Biochemistry and Microbiology, SciLifeLab Uppsala, The Biomedical Center, University of Uppsala, 75123 Uppsala, Sweden.
  • Götte M; Department of Gynecology and Obstetrics, Münster University Hospital, Vesaliusweg 2-4, 48149 Münster, Germany.
  • Bendas G; Cells-in-Motion Interfaculty Center (CiMIC), University of Münster, 48149 Münster, Germany.
ACS Pharmacol Transl Sci ; 7(8): 2484-2495, 2024 Aug 09.
Article de En | MEDLINE | ID: mdl-39144559
ABSTRACT
The deregulation of cell surface heparan sulfate proteoglycans (HSPGs) is a main issue of cancer cells for increasing their malignancy. In these terms, the sulfation pattern of HS, created by an orchestrated activity of enzymes balancing a site-specific sulfation, is of key importance. These enzymes are often deregulated by epigenetic processes in cancer, e.g., being silenced by DNA hypermethylation. Here, we address this issue in human breast cancer cell lines aiming to target epigenetic processes to reactivate HS sulfation, shifting HS into an antithrombotic phenotype for which 3-O-sulfation is particularly important. Treatment of MCF-7 and MDA-MB-231 cells with nontoxic concentrations of 5-azacytidine (azacytidine) and 5-fluoro-2'-deoxycytidine (FdCyd) as DNMT inhibitors or vorinostat for targeting HDAC increased HS3-O-sulfation remarkably, as confirmed by fluorescence microscopy, by upregulating HS3-O-sulfotransferases, detected by quantitative real-time polymerase chain reaction and Western blot. Flow cytometry and microscopic approaches confirm that upon inhibitor treatment, increased HS3-O-sulfation improves cell binding to antithrombin, leading to an antithrombotic activity. Nevertheless, only azacytidine- and vorinostat-treated cells display anticoagulative properties, represented by attenuated thrombin formation, a lower activation of human platelet aggregation, or ATP release. In contrast, FdCyd additionally upregulated tissue factor expression in both cell lines, overshadowing the anticoagulant effects of HS, leading to an overall prothrombotic phenotype. Our data provide evidence for the first time that targeting epigenetic processes in HS sulfation is a valuable means to foster anticoagulative cell properties for decreasing malignancy and metastatic potency. These data warrant further investigations to fine-tune epigenetic targeting and to search for potential biomarkers attributed to these activities.

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: ACS Pharmacol Transl Sci Année: 2024 Type de document: Article Pays d'affiliation: Allemagne Pays de publication: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: ACS Pharmacol Transl Sci Année: 2024 Type de document: Article Pays d'affiliation: Allemagne Pays de publication: États-Unis d'Amérique